Clinical study of Xingnaojing Injection combined with Alteplase in the treatment of acute ischemic stroke
LIANG Jianjun1 TANG Rong1 LI Hua2 LIANG Yong2 XU Fei1
1.Department of Emergency, 3201 Hospital Affiliated to Medical College of Xi′an Jiaotong University, Shannxi Province, Hanzhong 723000, China;
2.Department of Neurology, 3201 Hospital Affiliated to Medical College of Xi′an Jiaotong University, Shannxi Province, Hanzhong 723000, China
Abstract：Objective To investigate the clinical effect of Xingnaojing Injection combined with Ateplase in the treatment of acute ischemic stroke. Methods From March 2015 to March 2019, a total of 86 patients with acute ischemic stroke admitted to 3201 Hospital Affiliated to Medical College of Xi′an Jiaotong University were selected. They were divided into the control group and the study group according to the random number table method, with 43 cases in each group. The control group was treated with Alteplase, while the study group was treated with Xingnaojing Injection on the basis of the control group. The clinical efficacy, inflammatory factors, internal carotid artery blood flow, degree of nervous functional defects, daily activity ability and adverse reactions of the two groups were compared. Results The total effective rate of the study group after treatment was significantly higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). There was no statistically significant difference in interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) between the two groups of patients before treatment (P ＞ 0.05). After treatment, IL-6, TNF-α and hs-CRP of patients in both groups decreased compared with before treatment, and those in the study group were lower than those in the control group, the differences were statistically significant (P ＜ 0.05). The blood flow of basilar artery, anterior, middle and posterior cerebral artery and vertebral artery of patients of the two groups before treatment showed no significant difference (P ＞ 0.05). After treatment, the blood flow of basilar artery, anterior, middle and posterior cerebral artery and vertebral artery increased of patients in both groups, and those in the study group were higher than the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the score of neurological deficit degree (NIHSS), the score of modified Barthel index (mBI) between the two groups of patients (P ＞ 0.05). After treatment, the NIHSS score of patients of the two groups decreased compared with that before treatment, while the mBI score increased compared with that before treatment. After treatment, the NIHSS score of the study group was lower than that of the control group, while the mBI score was higher than that of the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions of patients between the two groups (P ＞ 0.05). Conclusion Xingnaojing Injection combined with Alteplase in the treatment of acute ischemic stroke has a definite effect, can effectively improve the level of inflammatory factors and internal carotid artery blood flow, and has a good safety, with certain clinical application value.
2020, Vol. 17 
京公网安备 11010502046598号